Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789538 | 0.86 | ALOX15 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2CYP2C19 | |
| SCHEMBL8354088 | 0.86 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| Hydrochloric Acid SCHEMBL29015997 | 0.86 | ALOX15 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2CYP2C19 | |
| SCHEMBL7336991 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2030044 | 0.84 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL29102862 | 0.84 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL10828679 | 0.83 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL25712841 | 0.83 | KDM4E (0.39) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7781357 | 0.82 | POLB (0.39) | CYP3A4HTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL26566724 | 0.82 | CYP3A4 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4578860-A1 | CYCLOALKYNE DERIVATIVE | PeptiDream Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-120092006-A | Cycloalkyne derivatives | 肽梦想株式会社 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024043341-A1 | CYCLOALKYNE DERIVATIVE | ペプチドリーム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-110337442-B | Novel glucose derivatives as inhibitors of sodium-dependent glucose transporter type 2 | 东亚ST株式会社 | 2023-05-12 | — | — | CN | disclosed |
| US-20170354639-A1 | DITERPENOID DERIVATIVES AND METHODS OF USE THEREOF | BIOGEN MA INC. | 2017-12-14 | — | — | US | disclosed |
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-7449468-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-5300638-A | Reacting imine derivative of threonine with an acetyl halide in the presence of a base; preferential | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0525589-A1 | Asymmetric synthesis of taxol side chain | Bristol-Myers Squibb Company (US) | 1993-02-03 | — | — | EP | disclosed |
| EP-0154132-B1 | 6-ALKYLIDENE PENEMS, THEIR PREPARATION AND USE, AND INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1992-01-08 | — | — | EP | disclosed |
| EP-0188247-B1 | PROCESS FOR PREPARING AZETIDINONE INTERMEDIATES | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-04-03 | — | — | EP | disclosed |
| US-4798828-A | LACTAMASE INHIBITORS | BEECHAM GROUP P.L.C. (GB) | 1989-01-17 | — | — | US | disclosed |
| US-4771134-A | Ring-opening process for preparing azetidinone intermediates | FARMITALIA CARLO ERBA S.P.A. (IT) | 1988-09-13 | — | — | US | disclosed |
| EP-0232966-A1 | Process for the preparation of penem compounds and intermediates for this preparation | BEECHAM GROUP PLC (GB) | 1987-08-19 | — | — | EP | disclosed |
| EP-0188247-A1 | Process for preparing azetidinone intermediates | FARMITALIA CARLO ERBA S.r.l. (IT) | 1986-07-23 | — | — | EP | disclosed |
| EP-0154132-A1 | 6-Alkylidene penems, their preparation and use, and intermediates | BEECHAM GROUP PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
| EP-0120613-A1 | Penem derivatives and precursors | BEECHAM GROUP PLC (GB) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | SMYD2 4308/4885CYP3A4 269/4885HTT 3008/4885 |
| US-20170354639-A1 | DITERPENOID DERIVATIVES AND METHODS OF USE THEREOF | KEAP1, NFE2L2, HMOX1 | SMYD2 4461/4885CYP3A4 1725/4885HTT 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.